Protocol Ledger

NCT06328777 · Phase II/III · RECRUITING

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Interventional Phase II/III clinical trial protocol NCT06328777 sponsored by Cabaletta Bio in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-02 Enrollment: 37 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06328777
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)37 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06328777
Protocol FieldVerified Registry Value
NCT IdentifierNCT06328777
Consolidated Lead SponsorCabaletta Bio
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment37 participants (ESTIMATED)
Registered Start Date2024-07-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI